Industry research reveals a stark reality: clinical trials cost pharmaceutical companies $50,000 per day to operate, but the real cost of delay is far steeper—$1 million per day in lost drug sales while life-saving therapies sit waiting for approval. In 2024 , more than one in five clinical trials experienced delayed start dates, a dramatic increase from just 4.5% two decades earlier. The culprit? Not failed science, but failed data infrastructure. The solution lies in strategic Crystal Reports to Power BI migration—a transformation that requires specialized expertise in both legacy system conversion and pharmaceutical regulatory requirements.
Consider the numbers: 90% of clinical trials face at least a month-long delay, with nearly half of these delays traced directly to data management and contracting bottlenecks. A recent analysis of oncology trials found pharmaceutical companies taking an average of 300 days—nearly 10 months—from the moment they had analyzed trial results to when those findings reached the medical community. During those 300 days, patients waited, competitors advanced, and opportunities evaporated.
For a pharmaceutical manufacturer running legacy Crystal Reports systems, the impact compounds daily. Static reports that once took 3-5 business days to generate now represent a critical vulnerability in an industry where speed quite literally saves lives. When adverse event patterns emerge in a Phase III trial monitoring thousands of patients across dozens of global sites, waiting even 48 hours for manual data compilation can mean the difference between early intervention and escalating safety concerns. The question facing pharmaceutical leaders in 2025 isn’t whether to modernize data infrastructure—it’s whether they can afford another day without it.
The Urgency of Change: Why Pharma Can’t Afford Legacy Reporting The Pharma Industry’s Data Dilemma: Outgrowing Static Crystal Reports Traditional Crystal Reports create significant obstacles in today’s fast-paced pharmaceutical environment. These legacy systems offer static snapshots rather than dynamic insights, making real-time decision-making nearly impossible. The inability to quickly access and analyze data isn’t just inconvenient—it’s a fundamental barrier to innovation and patient safety.
Why traditional Crystal Reports fall short for modern pharmaceutical data analytics: Crystal Reports deliver fixed, non-interactive outputs that show data from a single point in time. Clinical trial managers monitoring adverse events across multiple sites need dynamic dashboards that allow real-time filtering, drilling down into patient-level details, and comparing trends across demographics. Moreover, static PDFs simply cannot support this level of interactive pharmaceutical data analysis .
How legacy BI systems impact drug development and regulatory compliance: Drug development requires continuous monitoring and rapid adjustments across clinical phases, batch releases, and pharmacovigilance activities. Static reports force teams to regenerate outputs for every query change, creating bottlenecks. However, in a compliance-driven industry where regulators expect proactive monitoring and transparent audit trails, reactive snapshots fall dangerously short.
The true cost of manual reporting processes: Preparing legacy reports demands extensive manual data extraction, spreadsheet manipulation, and human verification. This time-consuming, error-prone process wastes valuable resources. Every hour spent compiling reports is time not spent analyzing data for breakthrough therapies, optimizing manufacturing, or enhancing patient safety protocols. Moreover, these delays directly impact business outcomes and patient care.
Challenges with data silos in pharmaceutical operations: Crystal Reports typically connect to individual databases, creating isolated information pockets. And, the data from R&D, manufacturing, quality control, and sales remains fragmented. A comprehensive view of the complete drug lifecycle—from discovery to commercialization—becomes virtually impossible. Moreover, understanding how raw material changes affect manufacturing yield and drug efficacy requires integrating disparate systems, which legacy tools make extraordinarily difficult.
Inability to integrate with advanced analytics and AI: The pharmaceutical industry increasingly relies on AI and machine learning for drug discovery, personalized medicine, and supply chain optimization. And, legacy reporting tools cannot integrate with these advanced capabilities. Moreover, they lack the architectural flexibility to feed real-time data to AI models or display AI-driven predictions accessibly. This prevents pharma companies from fully leveraging their data for breakthrough research and operational efficiencies.
The Critical Need for Real-Time Insights in 2025 Patient lives, billions in R&D investment, and stringent regulatory requirements all depend on accurate, timely data. This transcends business efficiency—it’s about public health and ethical responsibility.
Consider real-time pharmacovigilance monitoring : The ability to rapidly identify adverse event patterns across millions of patient records can prevent health crises. Additionally, interactive dashboards flag anomalies immediately, enabling swift investigation across global markets. Without these capabilities, critical safety signals get buried in mountains of static reports, potentially harming patients.
For R&D teams pursuing accelerated drug development timelines , real-time insights cut months or years off development cycles. Researchers analyzing experimental data, identifying promising compounds, and pivoting strategies based on early results need immediate access to dynamic intelligence. According to industry research, pharmaceutical companies can now complete processes that previously took months in less than five minutes using modern data platforms.
Regulatory compliance in pharmaceutical manufacturing demands rigorous data integrity and comprehensive audit trails. From GMP (Good Manufacturing Practices) to 21 CFR Part 11 requirements for electronic records, every data point needs traceability and auditability. However, static reports generated through manual, non-auditable processes make demonstrating control extremely challenging. The inability to quickly access current data for audits can lead to significant fines, production halts, and reputational damage.
The pharmaceutical sector cannot afford technological limitations. The urgent need for real-time insights is a fundamental requirement for success, safety, and innovation.
Unleashing the Power of Data: The Microsoft Power BI Advantage for Pharma Microsoft Power BI transforms static data into dynamic, actionable insights, catalyzing data-driven drug development and operational excellence. It’s not just a reporting tool—it’s a strategic platform for understanding entire operations and enabling proactive responses to business challenges.
Real-time monitoring and interactive dashboards for pharmacovigilance: Interactive Power BI dashboards display adverse event rates by drug, dose, patient demographics, or geography, updating as new data arrives. Additionally, clinical trial managers monitor patient recruitment, assess site performance, track safety signals, and manage data quality with dynamic visualizations. And, teams drill down from aggregate views to individual patient records with simple clicks, making investigations efficient and targeted. This represents a quantum leap in pharmaceutical safety analytics .
Enhanced regulatory compliance and data integrity: Power BI supports compliance through key capabilities aligned with regulatory standards:
Supporting GMP compliance and ALCOA+ principles: Power BI integrates with Manufacturing Execution Systems (MES) and ERP systems, providing real-time visibility into production processes. Dashboards track batch records, equipment calibration schedules, environmental monitoring, and deviation management against GMP standards. Adhering to ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, Available) becomes significantly easier with structured data models and automated refresh schedules.Automated reporting for FDA, EMA, and 21 CFR Part 11 compliance: Power BI automates routine compliance reports required by regulatory bodies. Once validated, data models and reports update automatically on schedule, reducing human error risks. When properly implemented with supporting systems, Power BI supports electronic signatures and comprehensive audit trails, aligning with 21 CFR Part 11 requirements.Streamlining audit readiness: With all critical data consolidated and presented consistently within Power BI, audit preparation time reduces drastically. Moreover, auditors can access secure, read-only interactive reports, exploring data points, verifying compliance measures, and tracing data lineage efficiently. This transparency builds regulatory trust and demonstrates robust control environments.Self-service analytics empowering pharmaceutical teams: Power BI democratizes data access across organizations. Researchers create ad-hoc analyses and explore data without IT tickets, testing hypotheses and analyzing results faster. Additionally, sales teams monitor market trends, territory performance, and efficacy data directly, tailoring strategies to real-time market shifts. Moreover, self-service pharmaceutical business intelligence fosters inquiry, accelerates decision-making, and empowers every department to become data-driven.
Advanced analytics and AI capabilities: Power BI natively integrates with Microsoft Azure AI services, enabling sophisticated applications:
Drug discovery: AI models analyze complex genomic data to identify potential candidates, predict compound efficacy, and uncover novel biomarkersSupply chain optimization: Predictive analytics forecast demand accurately, optimize inventory across global networks, and anticipate disruptionsPatient outcomes analysis: Real-world evidence (RWE) analysis helps understand drug effectiveness in broader populations, refining treatment protocols and identifying personalized medicine opportunitiesCloud-native scalability and cost-efficiency: As a cloud-native platform, Power BI scales effortlessly from small datasets to petabytes. Whether managing single clinical trial data or entire global enterprise information, Power BI handles it. This elasticity means paying only for usage, reducing upfront infrastructure costs and allowing pharmaceutical companies to grow analytics capabilities without significant capital expenditure.
Power BI in Action: Critical Use Cases for Pharmaceutical Companies Clinical trial management and real-time patient data analysis: Large Clinical Research Organizations (CROs) managing multiple global trials use Power BI dashboards to track recruitment progress, monitor adverse events by study arm, compare site performance, and visualize KPIs like data query resolution rates. Moreover, this real-time visibility identifies bottlenecks, ensures patient safety, and accelerates trial completion.
Supply chain visibility and demand forecasting: Power BI consolidates data from ERP, logistics, warehouse management, and external market sources for end-to-end visibility. Additionally, dashboards track inventory levels, monitor cold chain integrity for biologics, predict demand based on seasonal trends or public health data, and highlight potential delays or stock-out risks.
Manufacturing quality control and deviation management: Power BI integrates with MES and LIMS to monitor critical process parameters, track batch yields, and manage deviations. In addition to this, interactive dashboards help QA teams spot out-of-spec result trends, investigate root causes faster, and manage CAPAs more effectively, ensuring product quality and GMP compliance.
Drug safety and pharmacovigilance reporting: Pharmacovigilance teams aggregate adverse event reports from multiple sources and visualize trends in real-time. Additionally, users can interactively filter by drug, symptom, demographics, dosage, or time period, enabling faster signal detection, risk assessment, and regulatory reporting.
R&D pipeline optimization: Power BI visualizes entire drug development pipelines, tracking progress through phases, monitoring budget adherence, and identifying bottlenecks or resource constraints. Additionally, researchers can analyze experimental data, compare compound efficacy, and make data-driven decisions about which projects to advance.
Navigating the Migration Minefield: Why Expertise Matters Moving from Crystal Reports to Power BI sounds straightforward, but the path involves complex challenges requiring specialized expertise. Without proper guidance, transitions can quickly become minefields of delays, cost overruns, and compromised data integrity—especially critical in highly regulated pharmaceutical environments.
The Roadblocks to Modern Pharma Analytics: Why DIY Migrations Fail Crystal Reports generate static batch documents, while Power BI is an interactive analytical platform for dynamic data exploration. This fundamental difference requires complete re-envisioning of reports. What worked as a single large Crystal Report might need breaking into multiple interactive Power BI dashboards, each serving specific user needs.
Crystal Reports contain deeply nested formulas and intricate business logic built over years, sometimes with minimal documentation. Translating these accurately into Power BI’s DAX (Data Analysis Expressions) and Power Query M requires specialized skills. A single formula misinterpretation can produce incorrect calculations in regulatory reports, clinical analyses, or manufacturing metrics—catastrophic errors in pharma.
Crystal Reports often connect directly to transactional systems with inefficient table joins. Power BI thrives on optimized data models, typically Star Schemas designed for analytical performance and scalability. Moreover, re-engineering legacy data sources into robust models involves identifying facts and dimensions, building proper relationships, and ensuring data integrity across diverse pharma data sources.
Transitioning security models for sensitive data: Crystal Reports handle security at report levels or through basic user groups. Power BI offers advanced features like Row-Level Security (RLS), dynamically restricting data access based on user credentials. For pharmaceutical companies handling sensitive patient data, intellectual property, and confidential manufacturing information, implementing RLS correctly is paramount. Additionally, misconfiguration can cause severe data breaches and regulatory penalties.
Managing user adoption and change management: Even technically perfect migrations fail if users don’t embrace new systems. Pharmaceutical professionals need extensive training, ongoing support, and clear communication about Power BI benefits. Overcoming resistance, demonstrating immediate value, and ensuring seamless transitions are as important as technical aspects.
SQL Server Data Migration Tools: Expert Guide for Enterprises SQL Server data migration requires careful tool selection and strategic planning to avoid costly downtime and data loss
Learn More
The Hidden Costs of Inaction Compliance risks: Manual, error-prone reporting processes dramatically increase non-compliance risks. Missed audit trails, inaccurate data submissions, or delayed adverse event reporting can lead to hefty fines, product recalls, consent decrees, and severe reputational damage.
Operational inefficiencies: Extensive manual effort for generating, reviewing, and distributing legacy reports drains resources. Scientists, quality specialists, and analysts spend more time wrestling with data extraction than interpreting it, leading to slower decision-making and reduced productivity.
Missed innovation: The greatest hidden cost is opportunity loss. Without real-time, integrated, AI-ready data, pharmaceutical companies cannot fully leverage advanced analytics for drug discovery, personalized medicine, or optimized patient care. Moreover, they fall behind competitors embracing data as a strategic asset.
Kanerika understands the unique intricacies of pharmaceutical data, stringent regulatory environments, and legacy system migration challenges. And, our approach transforms data landscapes to empower innovation, ensure compliance, and drive measurable outcomes.
Our Proven IMPACT Framework At our methodology’s core is the IMPACT Framework—a structured yet agile approach for complex data modernization projects in regulated industries:
Identify growth opportunities and hidden challenges in pharmaceutical reporting through deep dives into existing environments and stakeholder collaboration
Map strategic and actionable data migration options, prioritizing reports based on business criticality and regulatory impact
Prove value through rapid pilots and targeted Power BI implementations, demonstrating tangible benefits firsthand
Analyze and showcase ROI from interactive dashboards and automated insights, tracking measurable improvements
Create clear roadmaps with defined milestones, establishing Power BI Centers of Excellence and planning future AI integrations
Transform business through agile execution and continuous improvement, providing comprehensive ongoing support
How to Migrate From Informatica to Databricks: Step-by-Step Migration Strategy Explore the key benefits, common challenges, and a clear step-by-step migration process.
Learn More
Unlocking Speed & Accuracy: FLIP Migration Accelerators Our proprietary FLIP Migration Accelerators significantly differentiate Kanerika’s approach. These intelligent tools overcome common Crystal Reports to Power BI migration roadblocks, reducing timelines, costs, and risks.
1. Automating up to 80% of migration tasks: FLIP accelerators automate Crystal Reports parsing, data model extraction, and formula conversion into Power Query M and DAX. This drastically cuts manual effort, allowing pharmaceutical teams to gain value from Power BI sooner—often reducing project duration by months.
2. Preserving complex business logic and data integrity: FLIP tools meticulously translate existing Crystal Reports logic, ensuring critical business rules, calculations, and transformations replicate accurately in Power BI. Additionally, this precision is vital for maintaining data integrity in regulated pharmaceutical environments where errors have severe implications.
3. Reducing manual effort and human error: Automating large conversion portions minimizes human error potential. This is particularly important for pharma data, where small inconsistencies can lead to compliance issues, flawed conclusions, or incorrect operational decisions.
4. Ensuring zero data loss and operational continuity: Accelerators include robust, multi-stage validation protocols ensuring no data loss or corruption during migration. We maintain operational continuity, keeping critical reporting functions uninterrupted throughout transitions.
Deep Pharma Expertise Our team comprises highly skilled Power BI experts with extensive pharmaceutical industry understanding. We know GMP versus GDP differences, understand 21 CFR Part 11 nuances, and are familiar with complex data structures in LIMS, MES, ERP, and clinical data management systems.
This expertise translates into:
Precise data modeling optimized for analytical performance and pharmaceutical data security requirementsAccurate DAX optimization reflecting complex pharmaceutical calculations for critical reportsIntuitive dashboard development tailored to diverse pharma users from R&D scientists to sales leadersComprehensive Data Validation Protocols Given pharmaceutical data’s high stakes, our migration process includes stringent, multi-stage validation protocols ensuring accuracy and consistency for regulatory requirements. Moreover, we implement comprehensive quality checks at every migration phase, rigorously reconcile Power BI reports against original sources, and provide detailed validation documentation for audit trails.
Dedicated Power BI Center of Excellence Setup Successful adoption extends beyond technology deployment. Kanerika helps establish robust Power BI Centers of Excellence fostering best practices, providing ongoing support, and managing future BI landscape growth. We provide tailored, role-based training programs for all pharmaceutical staff levels, focusing on real-world scenarios and empowering employees to confidently leverage Power BI.
The Challenge Dr. Reddy’s Laboratories, a prominent global pharmaceutical manufacturer, faced significant data management challenges. Additionally, their operations relied on fragmented data spread across multiple systems, creating inefficiencies in decision-making and operational visibility. Dr. Reddy’s realized they required a single, reliable source of truth to improve efficiency, speed up decision-making, and ultimately enhance patient care.
The company managed hundreds of different data sources including Oracle, SQL Server, File Systems, and Hive. Databases consisted of 100-5000 tables with data volumes ranging from 20GB to 2TB. This complexity made identifying data sensitivity across applications and maintaining governance policies extraordinarily challenging.
The Solution Kanerika’s solution centered around Power BI’s robust capabilities to unify, simplify, and enhance data management, creating a single, reliable source of truth that would streamline operations and accelerate decision-making.
Our team implemented a comprehensive pharmaceutical data integration strategy that:
Integrated 15+ disparate data sources into a unified Power BI platform Designed robust data governance architecture to identify and track sensitive information including PHI and PCI data Created new data security patterns custom to Dr. Reddy’s organizational needs Implemented advanced data classification for CCPA and HIPAA regulation compliance Established real-time monitoring capabilities for data security and operational insights For their AI-driven drug discovery initiatives, Dr. Reddy’s designed pipelines pulling information on more than two billion compounds from data sources to their data lake, processing close to 5,000 records per second—completing in less than five minutes what normally would take months.
The Impact The transformation delivered measurable improvements across Dr. Reddy’s operations:
Improved Decision-Making Speed: Real-time access to unified data enabled faster, more informed decisions across all departments. Leadership gained comprehensive visibility into products, delivery processes, and system data.Enhanced Data Accuracy and Security: The security team could easily identify any data security breach through the new architecture, enabling momentary action and easy identification of PHI and PCI sensitive information within the enterprise.Better Operational Efficiency: Streamlined data access and analytics processes reduced manual effort and accelerated workflows across R&D, manufacturing, and quality control functions.Enabled Regulatory Compliance: The solution enabled data readability for the data security team for CCPA and HIPAA regulation compliance, providing the detailed audit trails and governance frameworks required for pharmaceutical operations.Accelerated Innovation: The unified data platform positioned Dr. Reddy’s to leverage advanced AI and machine learning capabilities for drug discovery, quality control, and operational optimization.This client’s journey illustrates how strategic, expert-led Power BI implementation moves pharmaceutical companies from reactive, fragmented reporting to proactive, data-driven excellence—improving compliance, accelerating operations, enhancing product quality, and ultimately safeguarding patient safety.
Beyond Migration: Building a Future-Ready Pharma Data Ecosystem Migrating to Power BI is foundational, but true long-term value lies in building robust, future-ready data ecosystems that continuously drive innovation, optimize operations, and maintain compliance.
Fortifying Your Data Foundation: Enhanced Governance and Security 1. Implementing robust data governance with Microsoft Purview: We leverage Microsoft Purview to establish comprehensive, enterprise-wide data governance frameworks including data mapping, cataloging, lineage tracking, and clear ownership. For pharma, this ensures transparent traceability of critical data elements from clinical trials through manufacturing and supply chain, vital for regulatory audits.
Kanerika’s specialized governance suite:
KANGovern: Defines, implements, and enforces data policies, roles, and responsibilities across organizations, ensuring consistent data definitions and quality standardsKANComply: Automates compliance checks and audit trail generation for 21 CFR Part 11, HIPAA, GDPR, and GMP, proactively identifying potential gapsKANGuard: Focuses on protecting sensitive pharmaceutical data from unauthorized access, providing enhanced monitoring, threat detection, and response capabilities2. Maintaining data integrity and traceability: Our governance solutions ensure every data point has clear lineage and continuous validation against source systems, adhering to ALCOA+ principles. Additionally, this unbroken chain of custody is indispensable for GMP compliance and swift regulatory audit responses.
3. Enforcing compliance frameworks: We configure Power BI environments to meet requirements for ISO 27001, ISO 27701, SOC II, HIPAA, and GDPR, ensuring data ecosystems are powerful, compliant, and ethically responsible.
4. Integrating AI & Machine Learning The future of pharma is intrinsically linked with AI and machine learning capabilities. Power BI coupled with Kanerika’s AI/ML expertise acts as the crucial bridge to unlock these advanced capabilities.
5. Leveraging agentic AI for autonomous analysis: We integrate advanced AI models that autonomously analyze vast datasets, identify patterns, and generate predictive forecasts. Agentic AI can predict clinical trial dropout rates, identify early manufacturing defect indicators, or forecast drug demand based on epidemiological trends.
6. Custom generative AI solutions for R&D: Generative AI instantly summarizes lengthy clinical study reports, scientific publications, or regulatory submissions into concise briefings, or intelligently extracts key data from unstructured lab notes and research proposals. This significantly speeds information retrieval and decision-making in R&D.
Choose Kanerika: Your Strategic Partner for Unlocking Pharma’s Data Potential The journey from legacy Crystal Reports to modern Power BI ecosystems requires more than technical skills—it demands intimate understanding of business processes, compliance imperatives, and innovation vision.
Why Choose Kanerika? 1. Unrivaled expertise in highly regulated industries: Our team brings decades of combined experience helping pharmaceutical companies navigate complex data challenges. Additionally, we understand 21 CFR Part 11, GMP, HIPAA, GDPR, and other critical regulations, ensuring solutions are technically effective, fully compliant, and audit-ready.
2. Proprietary FLIP Migration Accelerators: Our unique accelerators significantly de-risk and speed migrations. Automating up to 80% of conversion tasks drastically reduces manual effort, minimizes errors, and guarantees sensitive pharma data integrity, delivering faster time to value.
3. Deep pharmaceutical compliance understanding: Compliance isn’t an afterthought—it’s integrated into every methodology phase. From secure data modeling and stringent validation to KANComply implementation, we ensure Power BI environments consistently exceed regulatory expectations.
4. Proven track record of measurable outcomes: Our detailed case studies demonstrably prove our ability to deliver tangible results: significantly reduced report generation times, faster issue resolution, improved operational visibility, and enhanced data integrity.
5. Comprehensive end-to-end support: We offer complete partnerships extending beyond initial migrations. Moreover, we establish Power BI Centers of Excellence, provide tailored training, and guide AI and machine learning integration, ensuring continuous evolution and maximum value.
6. Microsoft Solutions Partner status: Our prestigious status underscores our commitment to excellence, innovation, and client satisfaction. Partnering with Kanerika means partnering with a recognized leader in pharmaceutical data analytics consulting .
Take the Next Step: Embrace the Future of Pharma Analytics The pharmaceutical industry is at a pivotal moment. The choice is clear: remain limited by legacy reporting, risking compliance and slowing innovation, or embrace intelligent, real-time data analytics with Microsoft Power BI. This transformation offers efficiency gains plus the power to accelerate drug discovery, enhance patient safety, optimize manufacturing, and maintain competitive edges.
Your journey to superior pharmaceutical data insights begins with strategic, expert-led migration. Don’t let legacy system limitations hold back your innovation potential.
Schedule a personalized consultation with Kanerika’s Power BI experts today to discuss your Crystal Reports migration strategy and chart your path to advanced analytics. Visit https://www.kanerika.com/contact-us or explore our pharmaceutical BI solutions .
Frequently Asked Questions What are the main benefits of migrating from Crystal Reports to Power BI for pharmaceutical companies? Migrating to Power BI offers real-time interactive dashboards, enhanced regulatory compliance (21 CFR Part 11, GMP, HIPAA), robust self-service analytics, improved clinical trial data visualization, and seamless AI/ML integration. It replaces static manual reports with dynamic, actionable intelligence, accelerating drug development and ensuring patient safety.
How does Power BI ensure regulatory compliance in pharmaceutical settings?
Power BI for pharmaceutical analytics supports compliance through robust data governance features, secure data access (Row-Level Security), comprehensive audit trails, and Microsoft Purview integration. Kanerika’s KANComply solution automates compliance checks and documentation generation, helping pharmaceutical companies meet strict electronic records, data integrity, and patient privacy requirements.
What specific challenges does Kanerika address during Crystal Reports to Power BI migration?
Kanerika tackles converting intricate Crystal Reports formulas into Power BI DAX and Power Query M, re-engineering fragmented data models into optimized Star Schemas, implementing granular Row-Level Security for sensitive data, and efficiently managing large, undocumented report inventories. Our FLIP Migration Accelerators automate many tasks, ensuring accuracy and speed.
What is Kanerika's FLIP Migration Accelerator?
The FLIP Migration Accelerator is Kanerika’s proprietary toolset for Fast, Lean, Intelligent, and Precise migrations. It automates up to 80% of the Crystal Reports to Power BI conversion process, preserving complex business logic, reducing manual effort and errors, and ensuring zero data loss. This leads to faster project completion, lower costs, and guaranteed data integrity.
Can Power BI integrate with existing pharmaceutical systems?
Yes, Power BI integrates with Manufacturing Execution Systems (MES), Laboratory Information Management Systems (LIMS), Clinical Data Management Systems, and ERP platforms like SAP. Kanerika specializes in building robust, real-time data connections ensuring all critical operational, quality, and clinical data flows into Power BI for comprehensive analysis.
How does Power BI support advanced analytics and AI in drug discovery?
Power BI natively integrates with Microsoft Azure AI services, enabling pharmaceutical companies to leverage machine learning and custom generative AI solutions. This enables predictive forecasting for clinical trials, identification of new drug candidates through pattern analysis, supply chain demand prediction, and automated R&D document summarization.
What is the role of data governance in Kanerika's Power BI solutions?
Data governance is a cornerstone of Kanerika’s pharmaceutical Power BI solutions. We implement robust frameworks using Microsoft Purview and our specialized KANGovern, KANComply, and KANGuard tools. This ensures end-to-end data integrity, complete traceability, consistent data definitions, full regulatory compliance, and enhanced security against unauthorized access.
How long does a typical Crystal Reports to Power BI migration take?
Migration duration varies based on report quantity and complexity, data landscape size, and specific compliance requirements. However, Kanerika’s FLIP Migration Accelerators significantly reduce typical timelines, often automating tasks that traditionally take weeks or months into days or hours, leading to faster deployment and quicker value realization.
What training and support does Kanerika offer post-migration?
Kanerika provides comprehensive post-migration support including tailored, role-based training programs for all user levels—from basic Power BI navigation for business users to advanced DAX and data modeling for super-users and IT teams. We also assist in establishing Power BI Centers of Excellence for ongoing optimization and future analytical growth.
What are the main risks of delaying Power BI migration in pharmaceuticals?
Delaying migration prolongs reliance on outdated, static reporting, leading to increased compliance risks, significant operational inefficiencies from manual processes, and critical missed innovation opportunities in R&D, manufacturing, and patient care. The inability to access real-time, actionable insights severely hinders rapid decision-making, compromises patient safety, and erodes competitive advantage.
